Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population

International Journal of Medical Sciences

Volumn 10, Issue 1, 2012, Pages 60-67

  Laraqui, Abdelilah ^a,c   Uhrhammer, Nancy ^b   Lahlou Amine, Idriss ^a   El Rhaffouli, Hicham ^a   El Baghdadi, Jamila ^a   Mohamed, Dehayni ^a   Driss, Moussaoui Rahali ^a   Mohamed, Ichou ^a   Sbitti, Yassir ^a   Al Bouzidi, Abderrahman ^a   Amzazi, Said ^c   Bignon, Yves Jean ^b  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

^b CENTRE JEAN PERRIN   (France)

^c FACULTÉ DES SCIENCES   (Morocco)

Author keywords

BRCA1 mutations; Breast cancer; Unclassified variants

Indexed keywords

AMINO ACID; BRCA1 PROTEIN; CYSTEINE; GLYCINE;

ADULT; ALGERIA; ARTICLE; BREAST CANCER; DNA DETERMINATION; DNA SEQUENCE; EARLY CANCER; ETHNIC GROUP; EXON; FAMILIAL CANCER; FEMALE; FRAMESHIFT MUTATION; GENE FUNCTION; GENETIC CODE; GENETIC CONSERVATION; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOROCCO; MUTATIONAL ANALYSIS; ONSET AGE; OVARY CANCER; POPULATION RESEARCH; PREDICTION; TUMOR SUPPRESSOR GENE; TUNISIA;

BRCA1 MUTATIONS; BREAST CANCER; UNCLASSIFIED VARIANTS.;

ADULT; AGE OF ONSET; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; MIDDLE AGED; MOROCCO; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 84871352037     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5014     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
2. [Internet] Globocan. http://www-dep.iarc.fr/globocan/database.htm.
3. [Internet] Caducee. http://www.caducee.net/
4. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
5. Benider A, Bennani OM, Harif M, et al. Registre des cancers de la région du Grand Casablanca, Année 2004.
6. Tazi MA, Benjaafar N, Er-Raki A. Registre des Cancers de Rabat. Incidence des Cancers à Rabat, Année 2005; 2009.
7. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94: 1365-1372.
8. Easton DF, Hopper JL, Thomas DC, et al. Breast cancer risks for BRCA1/2 carriers. Science. 2004; 306: 2187-2191.
9. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 73: 1117-1130.
10. Pohlreich P, Zikan M, Stribrna J, et al. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res. 2005; 7: 728-736.
11. Carroll JC, Cremin C, Allanson J, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008; 54: 1691-1692.
12. Liede A, Narod SA. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat. 2002; 20: 413-4.
13. [Internet] Genetic testing for BRCA1 and BRCA2. http://www.cancer.gov/PDF/FactSheet.
14. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002; 30: 3894-4900.
15. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006; 43: 295-305.
16. Ng PC, Henikoff S: SIFT. Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003; 31: 3812-3814.
17. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993; 52: 678-701.
18. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265: 2088-2090.
19. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000; 92: 1529-1531.
20. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995; 11: 198-200.
21. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.
22. Uhrhammer N, Abdelouahab A, Lafarge L, et al. BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci. 2008; 5: 197-202.
23. Troudi W, Uhrhammer N, Sibille C, et al. Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet. 2007; 52: 915-920
24. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646.
25. Vahteristo P, Eerola H, Tamminen A, et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer. 2001; 84: 704-708.
26. Goelen G, Teugels E, Bonduelle M, et al. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet. 1999; 36: 304-308.
27. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999; 91: 943-949.
28. Cherbal F, Bakour R, Adane S, et al. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers. 2010; 28: 377-384.
29. Mahfoudh W, Bouaouina N, Ahmed SB, et al. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep. 2012; 39: 1037-1046.
30. Moller P, Heimdal K, Apold J, et al. Norwegian Inherited Breast Cancer Group, Norwegian Inherited Ovarian Cancer Group: Genetic epidemiology of BRCA1 mutations in Norway. Eur J Canc. 2001; 37: 2428-2434.
31. Vallon-Christersson J, Cayanan C, Haraldsson K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 2001; 10: 353-360.
32. Olopade OI, Fackenthal JD, Dunston G, et al. Breast cancer genetics in African Americans. Cancer. 2003; 97: 236-245.
33. Williams RS, Glover JN. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem. 2003; 278: 2630-2635.
34. Williams RS, Chasman DI, Hau DD, et al. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem. 2003; 278: 53007-16.
35. Worley T, Vallon-Christersson J, Billack B, et al. A naturally occurring allele of BRCA1 coding for a temperature sensitive mutant protein. Cancer Biol Ther. 2002; 1: 497-501
36. Vallon-Christersson J, Cayanan C, Haraldsson K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Human Mol Genet. 2001; 10: 353-360.
37. Carvalho MA, Marsillac SM, Karchin R, et al. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007; 67: 1494-1501.
38. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007; 81: 873-883.
39. Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by confirmation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000; 67: 841-50.